MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-07-2024
Revance Therapeutics Total Liabilities 2011-2026 | RVNC
Annual Total Liabilities Revance Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 630 M | 569 M | 463 M | 346 M | 115 M | 80.7 M | 26.9 M | 27.3 M | 22.6 M | 16.1 M | 180 M | 230 M | 195 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 630 M | 16.1 M | 223 M |
Quarterly Total Liabilities Revance Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 625 M | 625 M | 607 M | 630 M | 639 M | 571 M | 574 M | 569 M | 566 M | 565 M | 614 M | 463 M | 462 M | 455 M | 432 M | 346 M | 346 M | 346 M | 346 M | 115 M | 115 M | 115 M | 115 M | 80.7 M | 80.7 M | 80.7 M | 80.7 M | 26.9 M | 26.9 M | 26.9 M | 26.9 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 22.6 M | 22.6 M | 22.6 M | 22.6 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 56.2 M | 56.2 M | 56.2 M | 56.2 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 639 M | 16.1 M | 237 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 21.66 | 1.14 % | $ 1.01 B |  USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
4.9 M | $ 0.9 | -0.2 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
455 M | $ 22.33 | 1.66 % | $ 3.7 B | USA |
 |
Esperion Therapeutics
ESPR
|
768 M | $ 1.94 | 1.31 % | $ 403 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Galectin Therapeutics
GALT
|
146 M | $ 2.38 | 2.33 % | $ 152 M | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Greenwich LifeSciences
GLSI
|
1.56 M | $ 24.07 | -0.58 % | $ 313 M | USA |
 |
Heron Therapeutics
HRTX
|
242 M | $ 1.18 | -0.84 % | $ 197 M | USA |
 |
ImmuCell Corporation
ICCC
|
15.5 M | $ 8.26 | -1.07 % | $ 74.6 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
InflaRx N.V.
IFRX
|
13.7 M | $ 1.61 | 8.78 % | $ 152 M | Germany |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Innate Pharma S.A.
IPHA
|
151 M | $ 1.39 | 0.72 % | $ 235 M | France |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Inventiva S.A.
IVA
|
226 M | $ 5.11 | -0.78 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
57 M | $ 0.29 | -25.25 % | $ 676 K | USA |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
338 M | $ 19.09 | -2.75 % | $ 1.03 B | Britain |
 |
BioNTech SE
BNTX
|
2.76 B | $ 102.36 | -2.94 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.11 | 0.61 % | $ 439 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 23.18 | -0.34 % | $ 2.95 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.43 | -0.7 % | $ 381 M | Britain |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
111 M | $ 240.72 | 4.09 % | $ 4.4 B | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Eli Lilly and Company
LLY
|
36.6 B | $ 874.81 | -1.06 % | $ 785 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 2.9 | -0.34 % | $ 4.77 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |